HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathwayAlison Smith, Sarat Chandarlapaty|Nature Communications|2021Cited by 86
Tipifarnib potentiates the antitumor effects of PI3Kα inhibition in <i>PIK3CA</i> - and <i>HRAS</i> -dysregulated HNSCC via convergent inhibition of mTOR activityAlison Smith, Shivani Malik|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0